{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:24:43Z","timestamp":1787279083150,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients. Here, we report the development of AChR chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate autoreactive B cells producing anti-AChR autoantibodies. T cells were co-transduced with CAARs expressing extracellular domains of the AChR\u03b11 or \u03b21 subunits, enabling recognition of a broad range of pathogenic antibodies. AChR CAAR T cells selectively secreted effector cytokines upon activation, and efficiently lysed target cells. In a xenograft mouse model, they depleted pathogenic B cell lines and reduced autoantibody levels in the circulation and at the neuromuscular junction. These findings establish AChR CAAR T cells as a precision immunotherapy with the potential to achieve durable remission in refractory MG.<\/jats:p>","DOI":"10.1038\/s41467-026-76750-7","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:15:22Z","timestamp":1787231722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0476-9813","authenticated-orcid":false,"given":"Niels","family":"von Wardenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-9671","authenticated-orcid":false,"given":"Gregorio","family":"Spagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-3527","authenticated-orcid":false,"given":"S. Momsen","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wernick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-7549","authenticated-orcid":false,"given":"Hans-Christian","family":"Kornau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Zinnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5328-2740","authenticated-orcid":false,"given":"Amelya","family":"Keles Slevogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-1977","authenticated-orcid":false,"given":"Lucie Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie A.","family":"Homeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Blumenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7951-5730","authenticated-orcid":false,"given":"Maria","family":"Stecklum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-7275","authenticated-orcid":false,"given":"Nicholas","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0234-4790","authenticated-orcid":false,"given":"Minh C.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-419X","authenticated-orcid":false,"given":"Kevin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-7976","authenticated-orcid":false,"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"76750_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus, N. E. Myasthenia gravis. New Engl. J. Med. 375, 2570\u20132581 (2016).","journal-title":"New Engl. J. Med."},{"key":"76750_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02935610","volume":"5","author":"SJ Tzartos","year":"1991","unstructured":"Tzartos, S. J. et al. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol. Neurobiol. 5, 1\u201329 (1991).","journal-title":"Mol. Neurobiol."},{"key":"76750_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.39.8.1069","volume":"39","author":"VA Lennon","year":"1989","unstructured":"Lennon, V. A. & Griesmann, G. E. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology 39, 1069\u20131076 (1989).","journal-title":"Neurology"},{"key":"76750_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","volume":"83","author":"T Masuda","year":"2012","unstructured":"Masuda, T. et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 83, 935\u2013940 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"76750_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","volume":"144","author":"N Rose","year":"2022","unstructured":"Rose, N. et al. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. Acta Neuropathol. 144, 1005\u20131025 (2022).","journal-title":"Acta Neuropathol."},{"key":"76750_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham, M. C. et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 146, 319\u2013336 (2023).","journal-title":"Acta Neuropathol."},{"key":"76750_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Dis. Primers 5, 30 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"76750_CR8","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.cell.2025.03.004","volume":"188","author":"H Li","year":"2025","unstructured":"Li, H. et al. Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures. Cell 188, 2390\u20132406 (2025).","journal-title":"Cell"},{"key":"76750_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio, R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat. Rev. Neurol. 20, 84\u201398 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"76750_CR10","doi-asserted-by":"publisher","first-page":"e70262","DOI":"10.1111\/ene.70262","volume":"32","author":"G Spagni","year":"2025","unstructured":"Spagni, G. et al. Validation of the \u201cpatient-acceptable symptom state\u201d question as outcome measure in AChR myasthenia gravis: a multicentre, prospective study. Eur. J. Neurol. 32, e70262 (2025).","journal-title":"Eur. J. Neurol."},{"key":"76750_CR11","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza, M. et al. Patient-acceptable symptom states in myasthenia gravis. Neurology 95, e1617\u2013e1628 (2020).","journal-title":"Neurology"},{"key":"76750_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung, J. B. et al. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat. Rev. Immunol. 24, 830\u2013845 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"76750_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104\u20131105 (2023).","journal-title":"Lancet Neurol."},{"key":"76750_CR14","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A. et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann. Rheum. Dis. 83, 1597\u20131598 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"76750_CR15","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","volume":"112","author":"J Motte","year":"2024","unstructured":"Motte, J. et al. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron 112, 1757\u20131763 (2024).","journal-title":"Neuron"},{"key":"76750_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"76750_CR17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","volume":"16","author":"DS Tian","year":"2024","unstructured":"Tian, D. S. et al. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol. Med. 16, 966\u2013987 (2024).","journal-title":"EMBO Mol. Med."},{"key":"76750_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","volume":"23","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A., Schett, G. & Mougiakakos, D. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol. 23, 615\u2013624 (2024).","journal-title":"Lancet Neurol."},{"key":"76750_CR19","doi-asserted-by":"publisher","first-page":"103621","DOI":"10.1016\/j.eclinm.2025.103621","volume":"90","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial. EClinicalMedicine 90, 103621 (2025).","journal-title":"EClinicalMedicine"},{"key":"76750_CR20","doi-asserted-by":"crossref","unstructured":"Dye, B. et al. Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies\u2014a review. Am. J. Med. Sci. 371, 170\u2013178 (2025).","DOI":"10.1016\/j.amjms.2025.10.007"},{"key":"76750_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"76750_CR22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229\u20131238 (2023).","journal-title":"Nat. Biotechnol."},{"key":"76750_CR23","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","volume":"186","author":"SM Reincke","year":"2023","unstructured":"Reincke, S. M. et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell 186, 5084\u20135097 e18 (2023).","journal-title":"Cell"},{"key":"76750_CR24","doi-asserted-by":"publisher","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","volume":"9","author":"G Kordas","year":"2014","unstructured":"Kordas, G. et al. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS ONE 9, e108327 (2014).","journal-title":"PLoS ONE"},{"key":"76750_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jneuroim.2007.06.014","volume":"189","author":"S Sideris","year":"2007","unstructured":"Sideris, S. et al. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture. J. Neuroimmunol. 189, 111\u2013117 (2007).","journal-title":"J. Neuroimmunol."},{"key":"76750_CR26","doi-asserted-by":"publisher","first-page":"e0185976","DOI":"10.1371\/journal.pone.0185976","volume":"12","author":"T Makino","year":"2017","unstructured":"Makino, T. et al. Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools. PLoS ONE 12, e0185976 (2017).","journal-title":"PLoS ONE"},{"key":"76750_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"76750_CR28","doi-asserted-by":"publisher","first-page":"eadt0795","DOI":"10.1126\/sciadv.adt0795","volume":"11","author":"S Oh","year":"2025","unstructured":"Oh, S. et al. Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Sci. Adv. 11, eadt0795 (2025).","journal-title":"Sci. Adv."},{"key":"76750_CR29","doi-asserted-by":"publisher","first-page":"e214150","DOI":"10.1212\/WNL.0000000000214150","volume":"105","author":"K Oved","year":"2025","unstructured":"Oved, K. et al. Subunit-specific immunodominance in clinically distinct populations with AChR+ myasthenia gravis: a multiparametric cross-sectional analysis. Neurology 105, e214150 (2025).","journal-title":"Neurology"},{"key":"76750_CR30","doi-asserted-by":"publisher","first-page":"e213498","DOI":"10.1212\/WNL.0000000000213498","volume":"104","author":"P Zara","year":"2025","unstructured":"Zara, P. et al. Risk of false acetylcholine receptor autoantibody positivity by radioimmunoprecipitation assay in clinical practice. Neurology 104, e213498 (2025).","journal-title":"Neurology"},{"key":"76750_CR31","doi-asserted-by":"publisher","first-page":"e200331","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit, F. et al. Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol. Neuroimmunol. Neuroinflammation 12, e200331 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"76750_CR32","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.2024025413","volume":"145","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos, D., Meyer, E. H. & Schett, G. CAR T cells in autoimmunity: game changer or stepping stone? Blood 145, 1841\u20131849 (2025).","journal-title":"Blood"},{"key":"76750_CR33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","volume":"32","author":"M Caballero-\u00c1vila","year":"2022","unstructured":"Caballero-\u00c1vila, M. et al. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscul. Disord. 32, 664\u2013671 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"76750_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jneuroim.2004.10.002","volume":"159","author":"L Psaridi-Linardaki","year":"2005","unstructured":"Psaridi-Linardaki, L. et al. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J. Neuroimmunol. 159, 183\u2013191 (2005).","journal-title":"J. Neuroimmunol."},{"key":"76750_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1073\/pnas.79.1.188","volume":"79","author":"SJ Tzartos","year":"1982","unstructured":"Tzartos, S. J., Seybold, M. E. & Lindstrom, J. M. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 79, 188\u2013192 (1982).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76750_CR36","unstructured":"Volkov, J. R. et al. Clinical and translational findings following MuSK-CAART infusion without preconditioning in patients with Myasthenia Gravis (MuSCAARTesTM trial), in 2024 ESGCT Annual Congress. https:\/\/d1io3yog0oux5.cloudfront.net\/_04cf3169f5301302eacd5bfa557a5651\/cabalettabio\/db\/947\/8239\/pdf\/MuSK+CAART+Poster+ESGCT+2024.pdf (2024)."},{"key":"76750_CR37","unstructured":"Correlative findings following DSG3-CAART infusion with & without preconditioning in patients with Pemphigus Vulgaris (DesCAARTesTM trial), in 2024 ESGCT Annual Congress. https:\/\/d1io3yog0oux5.cloudfront.net\/_04cf3169f5301302eacd5bfa557a5651\/cabalettabio\/db\/947\/8241\/pdf\/2024+ESGCT+Oral+Presentation.pdf (2024)."},{"key":"76750_CR38","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","volume":"32","author":"T Vu","year":"2026","unstructured":"Vu, T. et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat. Med. 32, 1131\u20131141 (2026).","journal-title":"Nat. Med."},{"key":"76750_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41587-026-03001-x","volume":"44","author":"F Solimani","year":"2026","unstructured":"Solimani, F. et al. Clinical progress of engineered cellular immunotherapies for autoimmunity. Nat. Biotechnol. 44, 547\u2013562 (2026).","journal-title":"Nat. Biotechnol."},{"key":"76750_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-026-02633-4","volume":"11","author":"J Lu","year":"2026","unstructured":"Lu, J. et al. The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects. Signal Transduct. Target. Ther. 11, 192 (2026).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76750_CR41","doi-asserted-by":"publisher","first-page":"104060","DOI":"10.1016\/j.autrev.2026.104060","volume":"25","author":"M Larue","year":"2026","unstructured":"Larue, M. et al. Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives. Autoimmun. Rev. 25, 104060 (2026).","journal-title":"Autoimmun. Rev."},{"key":"76750_CR42","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/brain\/aww208","volume":"139","author":"J Kreye","year":"2016","unstructured":"Kreye, J. et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain 139, 2641\u20132652 (2016).","journal-title":"Brain"},{"key":"76750_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ana.25666","volume":"87","author":"HC Kornau","year":"2020","unstructured":"Kornau, H. C. et al. Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann. Neurol. 87, 405\u2013418 (2020).","journal-title":"Ann. Neurol."},{"key":"76750_CR44","doi-asserted-by":"publisher","first-page":"e200038","DOI":"10.1212\/NXI.0000000000200038","volume":"10","author":"G Spagni","year":"2023","unstructured":"Spagni, G. et al. Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis. Neurol. Neuroimmunol. Neuroinflammation 10, e200038 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"76750_CR45","doi-asserted-by":"publisher","first-page":"e200313","DOI":"10.1212\/NXI.0000000000200313","volume":"11","author":"G Spagni","year":"2024","unstructured":"Spagni, G. et al. Serological markers of clinical improvement in MuSK myasthenia gravis. Neurol. Neuroimmunol. Neuroinflammation 11, e200313 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76750-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76750-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76750-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:02:24Z","timestamp":1787277744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76750-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76750"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76750-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Related to this work, the German Center for Neurodegenerative Diseases (DZNE) has filed a patent application describing AChR CAAR T cells for the treatment of MG, on which H.P., S.M.R., N.v.W. and M.H. are named as inventors (PCT\/EP2021\/087201). G.S. has received public speaking honoraria and\/or consultation fees from Argenx, Alexion, and AMGEN. M.S. is employee of EPO GmbH. V.D. has received public speaking honoraria and compensation for advisory boards and\/or consultations fees from UCB, Alexion, Dianthus, Roche, Argenx, and Amgen. She declares no competing interest regarding this manuscript. K.C.O. has received research support from Argenx, Seismic Therapeutic, and Viela Bio (now Horizon Therapeutics\/Amgen). K.C.O. is an equity shareholder of Cabaletta Bio. K.C.O. serves on advisory boards for Merck (EMD Serono), Neurocrine Biosciences, and Seismic Therapeutic, and has received speaking fees from Amgen, argenx, and Immunovant. A.M. received speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion Pharmaceuticals, Argenx, Amgen, Axunio, Desitin, Grifols, Janssen, Merck, Novartis, Octapharma, Sanofi and UCB. He serves as member of the medical advisory board of the German Myasthenia Gravis Society (DMG e.V.) and chairman of the Association for Research in Myasthenic Syndromes in Germany (VEMSID e.V.). All other authors (S.W., H.C.K., A.K., L.Y.L., M.H., S.B., M.S., D.S., A.P., N.S., T.D., and M.P.) declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8730"}}